Key result
Allogeneic MSCs match autologous MSCs for functional outcomes and LVEF improvement in HFrEF.
Why the study?
Does allogeneic versus autologous MSC therapy improve functional outcomes and safety in patients with HFrEF?
Meta-Analysis (n=1,184)
Does allogeneic versus autologous MSC therapy improve functional outcomes and safety in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
Allogeneic MSCs appear to be as safe and effective as autologous MSCs in improving functional outcomes such as 6-minute walk distance and left ventricular end-diastolic volume in patients with HFrEF.
Recent randomized controlled trials have consistently demonstrated the safety and potential efficacy of MSC therapy for heart failure patients. This study delves into mesenchymal stem cells’ promising potential, offering a beacon of hope for the future of heart failure treatment with reduced ejection fraction (HFrEF). We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for this systematic review and meta-analysis. We searched four databases and registers for RCTs, including PubMed, EBSCO, clinicaltrials.gov, ICTRP, and other relevant websites. We then selected thirteen RCTs with 1184 participants based on our pre-defined inclusion/exclusion criteria. Two independent assessors extracted the data and performed a quality assessment. The data were then plotted for various outcomes, including death, hospitalization, major adverse cardiac events, pump function parameters, and 6-min walk distance. The safety of MSC-based treatment has been consistently demonstrated with MSCs from autologous ( Auto MSCs) and allogeneic ( Allo MSCs) sources. This reassuring finding underscores the reliability of MSC-based therapy irrespective of their source. However, Auto MSCs showed a trend toward greater protective benefits. Subgroup analysis revealed no significant differences between Auto MSCs and Allo MSCs in improving LVEF; 0.86% (95% CI − 1.21–2.94%) for Allo MSCs versus 2.17% (− 0.48%; 95% CI − 1.33–5.67%) for Auto MSCs. Allo MSCs significantly reduced end-diastolic volume (LVEDV) by − 2.08 mL (95% CI − 3.52—0.64 mL). Only Allo MSCs significantly improved 6-min walking distance (6-MWD); 31.88 m (95% CI 5.03–58.74 m) for Allo MSCs versus 31.71 m (95% CI − 8.91–71.25 m) for Auto MSCs. The exclusion of studies using adipose-derived cells resulted in even better safety and a significant improvement in LVEF for Allo MSCs treatment. Our findings suggest that Allo MSCs are at par with Auto MSCs in improving functional outcomes in heart failure patients. This underscores the need for future investigations in a larger patient cohort, emphasizing the urgency and importance of further research to fully understand the potential of MSCs in treating heart failure.
No takes yet. Share an insight, caveat, or question.
Tarek et al. (2025) conducted a meta-analysis in Heart failure with reduced ejection fraction (HFrEF) (n=1,184). Allogeneic mesenchymal stem cells (Allo MSCs) vs. Autologous mesenchymal stem cells (Auto MSCs) was evaluated on Improvement in left ventricular ejection fraction (LVEF). Allogeneic MSCs were comparable to autologous MSCs in improving functional outcomes in HFrEF patients, with no significant difference in LVEF improvement.
Synapse has enriched 10 related papers. Consider them for comparative context: